Shares of Relypsa Inc RLYP were trading higher by more than 2 percent at $28.60 early Thursday morning after the Daily Mail reported the company may be a potential acquisition target.
The Daily Mail reported that "rumors from across the Pond" suggest that AstraZeneca plc (ADR) AZN is eyeing another acquisition just weeks after acquiring ZS Pharma. The publication suggested that the company's CEO Pascal Soriot "now wants to take out" Relypsa –- ZS Pharma's biggest competitor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in